Myc can be transcriptionally regulated by BET bromodomain protein 4 (BRD4), and BET bromodomain inhibitor JQ1 selectively downregulates MYC and MYC-dependent target genes and showed anti-tumor effects of hematological malignancies and NSCLC [18,19]. This evidence concerns the gene BRD4 and hematologic disorder.